Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00578331 · ClinicalTrials.gov registry record · Phase 3
Safety Study of Olopatadine Nasal Spray
A Phase 3 study of Perennial Allergic Rhinitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 890
- Enrollment target
- 1
- Study location
NCT00578331 is a Phase 3 study of Perennial Allergic Rhinitis that has completed, run by Alcon Research. The registered enrollment target is 890 participants, above the 388-participant average among 4 other Perennial Allergic Rhinitis trials with a reported enrollment target (129% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00578331, a Phase 3 study of Perennial Allergic Rhinitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 890 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether olopatadine nasal spray is safe and effective when used for up to one year by patients with perennial allergic rhinitis.
Conditions Studied
Interventions
- DRUG Placebo Nasal Spray
- DRUG Olopatadine 0.6% nasal spray
Study Locations (1)
Texas
- Waco - Waco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 890 participants |
| Start Date | 2006-12 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00578331
The ClinicalTrials.gov registry entry for NCT00578331 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 890 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 388-participant average among 4 other Perennial Allergic Rhinitis trials with a reported enrollment target (129% higher). The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Perennial Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo Nasal Spray is the first listed.
NCT00578331 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00578331 about?
NCT00578331 is a clinical study titled "Safety Study of Olopatadine Nasal Spray". The purpose of this study is to determine whether olopatadine nasal spray is safe and effective when used for up to one year by patients with perennial allergic rhinitis.
What is the current status of trial NCT00578331?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 890 participants. The study started on 2006-12. Estimated completion is 2008-01.
What conditions does trial NCT00578331 study?
This clinical trial studies the following conditions: Perennial Allergic Rhinitis.
What interventions are being tested in trial NCT00578331?
The interventions under investigation include: Placebo Nasal Spray (DRUG), Olopatadine 0.6% nasal spray (DRUG).
Who is sponsoring clinical trial NCT00578331?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00578331 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Perennial Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)
COMPLETED · Phase 3
-
Evaluation of a Novel Questionnaire to Assess Patient Satisfaction With and Preference of Intranasal Corticosteroids for the Treatment of Allergic Rhinitis
COMPLETED · Phase 3
-
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
COMPLETED · Phase 4
-
Levocetirizine Effect on Nasal Nitric Oxide and Nasal Eosinophils in Subjects With Perennial Allergic Rhinitis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.